title: Measurement of urinary annexin V by ELISA and its significance as a new urinary-marker of kidney disease.
abstract: To confirm the significance of excretion of annexin V into the urine and the change of urinary annexin V concentration in kidney disease, a sandwich enzyme-linked immunosorbent assay (ELISA) was developed using two monoclonal antibodies. Urinary annexin V concentration was measured in healthy individuals and patients with kidney and other diseases. Urinary annexin V did not change over a range of pH between 5.0 and 8.0, and was stable during the course of the study for 24 h at room temperature and for 8 days at 4 degrees C. The mean urinary annexin V concentration in 105 normal healthy individuals was 1.5+/-1.5 ng/ml, while that in patients with nephrotic syndrome and systemic lupus erythematosis (SLE) nephritis was 9.3+/-9.1 and 6.6+/-6.7 ng/ml, respectively, and that in IgA nephropathy and chronic renal failure was 2.6+/-2.1 and 1.3+/-0.7 ng/ml, respectively. Annexin level correlated with urinary protein concentration (r=0. 717), but not the serum creatinine concentration, blood urea nitrogen (BUN) and 24-h creatinine clearance. Mean urinary annexin V concentration in patients with ischemic heart disease, hypertension, and diabetes mellitus was 1.4+/-1.0, 1.4+/-1.1, and 1.7+/-1.3 ng/ml, respectively. In one case of relapsing nephrotic syndrome, the urinary annexin V concentration was markedly increased in the early phase after admission and then decreased. This patient later required hemodialysis. These results suggest that a high urinary annexin V concentration may be an indicator of acute renal injury related to the urinary protein level.
authors.affiliation: Dokkyo University School of Medicine, Department of Cardiology and Pneumology, 880 Kitakobayashi, Mibu, 321-0293, Tochigi, Japan. ryukom@dokkyomed.ac.jp
authors.forename: R
authors.initials: R
authors.lastname: Matsuda
authors.forename: N
authors.initials: N
authors.lastname: Kaneko
authors.forename: Y
authors.initials: Y
authors.lastname: Horikawa
authors.forename: F
authors.initials: F
authors.lastname: Chiwaki
authors.forename: M
authors.initials: M
authors.lastname: Shinozaki
authors.forename: S
authors.initials: S
authors.lastname: Abe
authors.forename: W
authors.initials: W
authors.lastname: Yumura
authors.forename: H
authors.initials: H
authors.lastname: Nihei
authors.forename: T
authors.initials: T
authors.lastname: Ieiri
mesh_terms: D000328:Adult; D000368:Aged; D017304:Annexin A5 / Q000652:urine*; D015415:Biomarkers / Q000652:urine*; D015153:Blotting, Western; D003920:Diabetes Mellitus / Q000652:urine; D004355:Drug Stability; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005922:Glomerulonephritis, IGA / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D006973:Hypertension / Q000652:urine; D007674:Kidney Diseases / Q000652:urine*; D007676:Kidney Failure, Chronic / Q000652:urine; D008180:Lupus Erythematosus, Systemic / Q000652:urine; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000652:urine; D009404:Nephrotic Syndrome / Q000652:urine; D011507:Proteinuria / Q000652:urine; D012016:Reference Values
chemical_list: D017304:Annexin A5; D015415:Biomarkers